FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295751855> ?p ?o ?g. }

• W4295751855 abstract "Dyshidrosiform bullous pemphigoid (DBP) is a rare variant of bullous pemphigoid (BP), autoimmune blistering disease mostly affecting the elderly. DBP was described by Levine et al. in 1979, as pruritic blisters on hands and feet, resembling pompholyx, often generalizing to other body sites.1, 2 In pediatric population, dyshidrosiform presentation of BP is a constant initial BP manifestation in infants, while in adults the incidence of DBP ranges from 3.5% to 28%.2, 3 Steroids represent the primary treatment of BP, adding steroid-sparing agents when needed. Almost all adults and 93% of infants achieve remission.2, 3 Recurrences are reported in 12% of infants, especially after rapid steroid tapering. We report a case of DBP, successfully treated with intravenous immunoglobulins (IVIGs) after ineffective classical steroid therapy. A 1-month-old boy who developed pruritic blisters on his hands and feet, progressively generalizing (Figure 1), was referred to the dermatology clinic after ineffective impetigo treatment with amoxiclavulanate. At clinical examination, mucosae were spared, Nikolsky sign was negative, and generalized pruritic, tense, hemorrhagic bullae were evidenced raising suspicion of BP. Laboratory findings revealed leukocytosis (58,000/mm3), eosinophilia (24,000/mm3), and thrombocytosis (1,000,000/mm3). Skin biopsy was performed for histopathological examination and direct immunofluorescence (DIF), revealing respectively multiple eosinophils in the superficial dermis and in subepidermal clefts and linear staining of IgG and C3 along the dermoepidermal junction. Enzyme-linked immunosorbent assay (ELISA, commercial-kits EuroimmunAG) evidenced IgG anti-BP180-antigen (234.5 U/ml) and IgG anti-BP230-antigen (22.8 U/ml) (normal values <20 U/ml). Infantile BP (IBP) was diagnosed. Oral betamethasone was administered (0.2 mg/kg/day), obtaining clinical remission within 1 month; it was progressively tapered. A relapse after tapering was controlled with prednisone (25 mg/day) and dapsone (50 mg/day), but weight gain and insomnia forced to taper steroids, worsening BP. IVIGs were added (1 g/kg/day, 2-day-course, monthly, 6 months) with immediate clinical improvement, allowing tapering of prednisone (5 mg/day) and dapsone (25 mg/day) within 4 months, as remission was obtained after the fourth IVIGs administration. Dapsone (25 mg/day) was still administered for 1 year. During 2-year-follow-up no further relapses were reported; ELISA IgG autoantibodies were negative. BP represents the most common bullous autoimmune disease in adults, whereas pediatric BP is rarer.4 Acral dyshidrotic BP is the major presentation in infants (100% of IBP), with progressive generalization in 91%. Noteworthy, most DBP patients present tense bullae on hands and feet, resembling dyshidrosiform dermatitis, often evolving into haemorrhagic bullae “haemorrhagic pompholyx,” mostly generalizing, as in our case. Though no official treatment guidelines exist for IBP, steroids are administered as first-line therapy (97% of cases), adding steroid-sparing agents in 60% of patients. Overall, 93% obtain remission.3, 5 Dapsone is the mostly used steroid sparing agent (70%), effectively inhibiting neutrophilic chemotaxis and activity, and being well tolerated.3, 6 Occasionally, IBP may be refractory to systemic corticosteroids and dapsone, as in the present case: IVIGs (2 g/kg/4w) may be of aid in these circumstances, rapidly and safely leading to clinical improvement.2, 3 In literature cases of IBP treated with IVIGs are anecdotal, reporting variable dosages, (200–1000 mg/kg/day), number (1–7), duration (1–5 days) of infusion-courses and intervals between courses (2–5 weeks). Mostly, administered doses corresponded to the IVIG regimen of adults (400 mg/kg/day, 5 days) for autoimmune bullous diseases comprising BP.7 Reported cases mostly reached clinical remission after IVIG administration, permitting rapid taper of corticosteroids. No severe adverse effects attributable to IVIGs were reported.7 Conclusively, IVIG are a well-tolerated, effective, broad-spectrum therapeutic alternative for severe, therapy-refractory immune diseases as BP.5 However, the high costs limit IVIGs' use to selective indications.8 Still, in difficult-to-treat, fragile BP patients, as the presented one-month-old infant, IVIGs' safety and therapeutic potency highly favor their administration, which is mostly resolutive.5, 7 Gianmaria Viglizzo, Astrid Herzum, Emanuele Cozzani, Corrado Occella, and Aurora Parodi contributed equally to the manuscript and read and approved the final version of the manuscript. Open Access Funding provided by Universita degli Studi di Genova within the CRUI-CARE Agreement. The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript. The present research study complies with the guidelines for human studies and includes evidence that the research study was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. Written informed consent to publish the case (including publication of images) was obtained. The data that support the findings of this study are available from the corresponding author upon reasonable request." @default.
• W4295751855 created "2022-09-15" @default.
• W4295751855 creator A5008960145 @default.
• W4295751855 creator A5037288922 @default.
• W4295751855 creator A5070591722 @default.
• W4295751855 creator A5086282228 @default.
• W4295751855 creator A5088206921 @default.
• W4295751855 date "2022-09-27" @default.
• W4295751855 modified "2023-09-25" @default.
• W4295751855 title "Intravenous immunoglobulins in infantile dyshidrosiform bullous pemphigoid refractory to steroids and dapsone" @default.
• W4295751855 cites W1982846034 @default.
• W4295751855 cites W1987775826 @default.
• W4295751855 cites W2114104405 @default.
• W4295751855 cites W2159974752 @default.
• W4295751855 cites W3092613619 @default.
• W4295751855 cites W3154531750 @default.
• W4295751855 cites W4229055091 @default.
• W4295751855 cites W4280587459 @default.
• W4295751855 doi "https://doi.org/10.1111/dth.15826" @default.
• W4295751855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36101007" @default.
• W4295751855 hasPublicationYear "2022" @default.
• W4295751855 type Work @default.
• W4295751855 citedByCount "1" @default.
• W4295751855 countsByYear W42957518552022 @default.
• W4295751855 crossrefType "journal-article" @default.
• W4295751855 hasAuthorship W4295751855A5008960145 @default.
• W4295751855 hasAuthorship W4295751855A5037288922 @default.
• W4295751855 hasAuthorship W4295751855A5070591722 @default.
• W4295751855 hasAuthorship W4295751855A5086282228 @default.
• W4295751855 hasAuthorship W4295751855A5088206921 @default.
• W4295751855 hasBestOaLocation W42957518551 @default.
• W4295751855 hasConcept C142724271 @default.
• W4295751855 hasConcept C159654299 @default.
• W4295751855 hasConcept C16005928 @default.
• W4295751855 hasConcept C203014093 @default.
• W4295751855 hasConcept C25834368 @default.
• W4295751855 hasConcept C2775934546 @default.
• W4295751855 hasConcept C2777520566 @default.
• W4295751855 hasConcept C2777624698 @default.
• W4295751855 hasConcept C2777640609 @default.
• W4295751855 hasConcept C2778075117 @default.
• W4295751855 hasConcept C2778720950 @default.
• W4295751855 hasConcept C2779252107 @default.
• W4295751855 hasConcept C2780439664 @default.
• W4295751855 hasConcept C71924100 @default.
• W4295751855 hasConcept C90924648 @default.
• W4295751855 hasConceptScore W4295751855C142724271 @default.
• W4295751855 hasConceptScore W4295751855C159654299 @default.
• W4295751855 hasConceptScore W4295751855C16005928 @default.
• W4295751855 hasConceptScore W4295751855C203014093 @default.
• W4295751855 hasConceptScore W4295751855C25834368 @default.
• W4295751855 hasConceptScore W4295751855C2775934546 @default.
• W4295751855 hasConceptScore W4295751855C2777520566 @default.
• W4295751855 hasConceptScore W4295751855C2777624698 @default.
• W4295751855 hasConceptScore W4295751855C2777640609 @default.
• W4295751855 hasConceptScore W4295751855C2778075117 @default.
• W4295751855 hasConceptScore W4295751855C2778720950 @default.
• W4295751855 hasConceptScore W4295751855C2779252107 @default.
• W4295751855 hasConceptScore W4295751855C2780439664 @default.
• W4295751855 hasConceptScore W4295751855C71924100 @default.
• W4295751855 hasConceptScore W4295751855C90924648 @default.
• W4295751855 hasIssue "11" @default.
• W4295751855 hasLocation W42957518551 @default.
• W4295751855 hasLocation W42957518552 @default.
• W4295751855 hasLocation W42957518553 @default.
• W4295751855 hasOpenAccess W4295751855 @default.
• W4295751855 hasPrimaryLocation W42957518551 @default.
• W4295751855 hasRelatedWork W1991964801 @default.
• W4295751855 hasRelatedWork W2101880291 @default.
• W4295751855 hasRelatedWork W2103540400 @default.
• W4295751855 hasRelatedWork W2185848092 @default.
• W4295751855 hasRelatedWork W2768691462 @default.
• W4295751855 hasRelatedWork W2893172106 @default.
• W4295751855 hasRelatedWork W3154531750 @default.
• W4295751855 hasRelatedWork W4210644637 @default.
• W4295751855 hasRelatedWork W4301457614 @default.
• W4295751855 hasRelatedWork W89680061 @default.
• W4295751855 hasVolume "35" @default.
• W4295751855 isParatext "false" @default.
• W4295751855 isRetracted "false" @default.
• W4295751855 workType "article" @default.